Back HCV Treatment Approved HCV Drugs

Approved HCV Drugs

EASL 2016: DAAs for Hepatitis C Achieve Excellent Outcomes in Real-World Settings

Hepatitis C therapy with direct acting antivirals (DAAs) is as effective in real-world settings as it was in clinical trials, according to U.S. research presented at the International Liver Congress in Barcelona last week. Investigators from the Department of Veteran Affairs (VA) analyzed outcomes in over 9000 patients treated with DAA combinations. Outcomes were excellent, with 2 combinations achieving cure rates of 93%, similar to those seen in randomized studies with strict eligibility criteria and close follow-up.

alt

Read more:

FDA Approves Harvoni for Hepatitis C Patients with Advanced Liver Disease

The U.S. Food and Drug Administration (FDA) has approved an expanded indication for Gilead Sciences sofosbuvir/ledipasvir coformulation (Harvoni) plus ribavirin for genotype 1 chronic hepatitis patients with decompenated liver cirrhosis and for genotype 1 or 4 liver transplant recipients without cirrhosis or with compensated cirrhosis, the company announced this week.

alt

Read more:

AASLD 2015: High Cure Rate for People Retreated After Failure of Short Course DAA Therapy

Hepatitis C patients who did not achieve sustained virological response with a prior short course of direct-acting antiviral (DAA) therapy had a high likelihood of being cured if treated again with sofosbuvir/ledipasvir standard therapy, according to results from the SYNERGY study presented at the 2015 AASLD Liver Meeting last week in San Francisco. A related analysis showed that emergence of certain drug-resistance mutations was common during very short therapy, but this did not appear to compromise response to retreatment.

alt

Read more:

FDA Approves Daclatasvir + Sofosbuvir for Hard-to-Treat Hepatitis C Patients

The U.S. Food and Drug Administration (FDA) this month approved an expanded indication for Bristol-Myers Squibb's daclatasvir (Daklinza) and Gilead Sciences sofosbuvir (Sovaldi) for additional patient groups including people with HIV/HCV coinfection, patients with advanced liver cirrhosis, and liver transplant recipients.

alt

Read more:

AASLD 2015: HCV Triple Regimen Cures Rapid Responders in 3 Weeks

Response-guided therapy using an all-oral regimen of 3 direct-acting antivirals cured a majority of easier-to-treat genotype 1b hepatitis C patients in just 3 weeks, according to results from the small SODAPI pilot study, presented in a late-breaking poster at the AASLD Liver Meeting last week in San Francisco. Further research will be needed to see if these promising results hold for larger patient populations.

alt

Read more: